Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/155346
Title: | Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel |
Author: | Pasculli, Barbara Barbano, Raffaela Rendina, Michelina Fontana, Andrea Copetti, Massimiliano Mazza, Tommaso Valori, Vanna Maria Morritti, Maria Maiello, Evaristo Graziano, Paolo Murgo, Roberto Fazio, Vito Michele Esteller, Manel Parrella, Paola |
Keywords: | Micro RNAs Càncer de mama Tractament adjuvant del càncer MicroRNAs Breast cancer Adjuvant treatment of cancer |
Issue Date: | 17-Oct-2019 |
Publisher: | Nature Publishing Group |
Abstract: | MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P = 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656-1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517-1.000) and 10-years (AUC: 0.804. 95%CI: 0.517-1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR-210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41598-019-51581-3 |
It is part of: | Scientific Reports, 2019, vol. 9, num. 1, p. 14913 |
URI: | http://hdl.handle.net/2445/155346 |
Related resource: | https://doi.org/10.1038/s41598-019-51581-3 |
ISSN: | 2045-2322 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
695393.pdf | 2.09 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License